Pendahuluan. Pencegahan transmisi hepatitis C pada pasangan seksual pasien koinfeksi HIV/HCV merupakan upaya penatalaksanaan hepatitis C. Namun demikian, belum ada data prevalensi hepatitis C dan faktor yang berhubungan dengan transmisi hepatitis C pada pasangan seksual pasien koinfeksi HIV/HCV di Indonesia, sehingga perlu dilakukan penelitian untuk memperoleh data tersebut. Penelitian ini bertujuan untuk mengetahui prevalensi hepatitis C dan faktor-faktor yang berhubungan dengan kejadian hepatitis C pada pasangan seksual pasien koinfeksi HIV/HCV.Metode. Studi potong lintang pada pasangan heteroseksual pasien koinfeksi HIV/HCV yang berobat di Pokdisus RSCM. Faktor yang diteliti meliputi penggunaan narkotika suntik, transfusi darah, status HIV, penggunaan kondom, jumlah hubungan seksual, jumlah pasangan seksual, tipe hubungan seksual dan hitung CD4+ pasien koinfeksi HIV/HCV. Pengambilan data dilakukan dengan wawancara secara terpisah dan pemeriksaan darah antiHCV total dan antiHIV. Analisis statistik dilakukan dengan uji chi-square dan Fisher dan regresi logistik menggunakan program SPSS.Hasil. Selama periode Mei-Agustus 2008, diperoleh 119 subyek penelitian pada rentang usia 19-39 tahun (median 26 tahun) dan 95,8% diantaranya berjenis kelamin perempuan. Didapatkan prevalensi hepatitis C sebesar 10,1%. Hasil analisis bivariat kelompok subyek nonpengguna narkotika suntik didapatkan status HIV reaktif dan hubungan seksual nonvaginal berhubungan dengan kejadian hepatitis C. Pada hasil analisis multivariat didapatkan hanya tipe hubungan nonvaginal yang berhubungan dengan kejadian hepatitis C (adjusted RP 8,051; IK95% 1,215-53,353).Simpulan. Prevalensi hepatitis C pada pasangan seksual pasien koinfeksi HIV/HCV sebesar 10,1%. Tipe hubungan nonvaginal dan status antiHIV positif dapat meningkatkan risiko terjadinya kejadian hepatitis C sebesar 8 kali. Dibutuhkan studi lanjutan dengan sampel yang lebih besar dan desain yang lebih baik untuk menentukan transmisi seksual hepatitis C.

Background In this study, we aimed to investigate whether FIB-4 index is useful in predicting mortality in patients with concurrent hematological malignancies and COVID-19. We also aimed to determine the optimal cut-off point for the prediction. Methods This is a single-center retrospective cohort study conducted in Dharmais National Cancer Hospital, Indonesia. Consecutive sampling of adults with hematological malignancies and COVID-19 was performed between May 2020 and January 2021. COVID-19 screening test using the reverse transcriptase polymerase chain reaction (RT-PCR) of nasopharyngeal samples were performed prior to hospitalization for chemotherapy. FIB-4 index is derived from [age (years) × AST (IU/L)]/[platelet count (109/L) × √ALT (U/L)]. The primary outcome of this study is mortality, defined as clinically validated death/non-survivor during a 3-months (90 days) follow-up. Results There were a total of 70 patients with hematological malignancies and COVID-19 in this study. Median FIB-4 Index was higher in non-survivors (13.1 vs 1.02, p<0.001). FIB-4 index above 3.85 has a sensitivity of 79%, specificity of 84%, PLR of 5.27, and NLR of 0.32. The AUC was 0.849 95% CI 0.735–0.962, p<0.001. This cut-off point was associated with OR of 16.70 95% CI 4.07–66.67, p<0.001. In this study, a FIB-4 >3.85 confers to 80% posterior probability of mortality and FIB-4 <3.85 to 19% probability. FIB-4 >3.85 was associated with shorter time-to-mortality (HR 9.10 95% CI 2.99–27.65, p<0.001). Multivariate analysis indicated that FIB-4 >3.85 (HR 4.09 95% CI 1.32–12.70, p = 0.015) and CRP> 71.57 mg/L (HR 3.36 95% CI 1.08–10.50, p = 0.037) were independently associated with shorter time-to-mortality. Conclusion This study indicates that a FIB-4 index >3.85 was independent predictor of mortality in patients with hematological malignancies and COVID-19 infection.

Pendahuluan. Kesintasan pasien mieloma multipel (MM) aktif ditentukan oleh diagnosis dini dan berbagai faktor prognostik. Perkembangan kriteria diagnostik MM dari sebelumnya yaitu kriteria Durie-Salmon (DS) menjadi International Myeloma Working Group (IMWG) 2003 merupakan upaya mendiagnosis MM aktif lebih dini. Akan tetapi karena keterbatasan sumber daya, upaya pemenuhan kriteria diagnostik tersebut tidak dapat dilakukan secara konsisten di Indonesia. Berdasarkan hal tersebut, maka perlu diketahui proporsi pemenuhan diagnosis MM berdasarkan kriteria diagnostik DS dan IMWG 2003 serta dampaknya pada kesintasan pasien MM di Indonesia. Metode. Penelitian ini menggunakan desain kohort retrospektif dengan analisis kesintasan pada pasien MM aktif yang berobat di Rumah Sakit Cipto Mangunkusumo dan Rumah Sakit Kanker Dharmais selama tahun 2005-2015. Data disajikan dalam kurva Kaplan Meier dan tabel kesintasan dengan interval kepercayaan (IK) 95%. Hasil. Studi ini melibatkan 102 pasien MM aktif yang memiliki data penunjang diagnosis dan kesintasan lebih dari satu bulan.

BACKGROUND: Cisplatin-induced nephrotoxicity is the most common and devastating side effects which affects long-term outcome. It may be reversible in some patients but may also cause permanent kidney injury. AIM: This research aims to evaluate risk factors of cisplatin nephrotoxicity and unrecovered kidney function at national cancer hospital in Indonesia. METHODS: This is a retrospective and cohort study conducted at Dharmais National Cancer Hospital, Jakarta, Indonesia. All cancer patients aged 18 years old and above, who received cisplatin-based regimen as the first-line chemotherapy and completing all cycles with at least four cycles, were included in the study. Demographic data were collected and kidney function was evaluated using estimated glomerular filtration rate (eGFR) before, 3 times during chemotherapy, 1 and 3 months after the last dose. RESULTS: A total of 177 patients were included in the analysis, with mean age of 45.80 ± 11.75 years old, majority diagnosed with nasopharynx cancer (58.8%), and have baseline eGFR of 102.76 ± 20.68 mL/min 1.73m2. Nephrotoxicity is occurred in 80 (45.2%) patients with 27 (15.3%) toxicity occurred after the first cycle. Age above 50, hypertension and non-steroidal anti-inflammatory drugs (NSAID) use associated with increased risk of cisplatin-induced nephrotoxicity. Nephrotoxicity risk factors include age above 50 (OR 4.18, 95% CI 2.11–8.28; p < 0.0001), hypertension (OR 2.03, 95% CI 1.03–4.01; p = 0.040), and NSAID use (OR 2.34, 95% CI 1.22–4.93; p = 0.025). Risk factors of patients who unrecovered above 75% eGFR baseline were hypertension (OR 0.47, 95% CI 0.17–0.56; p = 0.001) and gender (OR 0.018, 95% CI 0.03–0.95; p = 0.043). CONCLUSION: Nephrotoxicity occurs in 45.2% patients throughout cisplatin-based chemotherapy cycles. Risk factors of nephrotoxicity includes age above 50, hypertension, and NSAID while hypertension and female gender are risk factor for not recover above 75% eGFR baseline after cisplatin cycles.

Background and Aim Most patients with non-small cell lung cancer (NSCLC) are diagnosed in advanced-stage disease and therefore have poor overall survival. It remains unclear whether nutritional status affects response rate and overall survival in NSCLC patients. This study aimed to evaluate the association of nutritional status with treatment response and overall survival in patients with advanced stage of NSCLC. Methods Patients aged ≥18 years with stage II–IV NSCLC (January–June 2018) in a national cancer center in Indonesia were enrolled in this study. The patients were followed up for 2 years since NSCLC diagnosis was established. Clinical data including age, sex, histology of cancer, disease stage, cachexia, and weight status before chemotherapy were reviewed and analyzed. Logistic regression and Cox regression analyses were performed. Results A total of 174 patients (71% males, mean age = 58±9.4 years) was included. Complete response was found in <1% patients, partial response 41%, stable disease 33%, and progressive disease 25%. Median survival was 12 months (95% CI: 11–13 months). Mortality rate was 5.7 per 100 person-months. Poor survival was associated with being males (HR: 1.77, 95% CI: 1.15–2.72, P = 0.009), and overweight or obesity (HR 1.67, 95% CI: 1.04–2.69, P = 0.034). These associations were independent of sex, age, staging, histopathology, performance status and D-dimer level at baseline. Cachexia and BMI at baseline were not associated with treatment response. Conclusion Males and having overweight or obesity are independently associated with lower survival in patients with advanced stage of NSCLC undergoing platinum-based chemotherapy.

Bank Mandiri won the best Financial Services Super App at the CNBC Indonesia Awards 2021 during the covid 19 pandemic. This study is to determine whether there are differences in bank performance before and after the covid pandemic. The methodology used is the Wilcoxon difference test because the data are not normally distributed. The results of statistical analysis state that there is no difference in bank performance or health at Bank Mandiri between before and after the COVID-19 pandemic.